Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Accumulated Expenses (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Accumulated Expenses for 12 consecutive years, with $154780.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 41.36% year-over-year to $154780.0, compared with a TTM value of $154780.0 through Sep 2025, down 41.36%, and an annual FY2024 reading of $126106.0, up 224.86% over the prior year.
  • Accumulated Expenses was $154780.0 for Q3 2025 at Abvc Biopharma, down from $160914.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.6 million in Q3 2023 and bottomed at $13819.0 in Q4 2022.
  • Average Accumulated Expenses over 5 years is $1.1 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses plummeted 98.94% in 2022, then soared 261.3% in 2025.
  • Year by year, Accumulated Expenses stood at $1.3 million in 2021, then tumbled by 98.94% to $13819.0 in 2022, then skyrocketed by 180.91% to $38819.0 in 2023, then skyrocketed by 224.86% to $126106.0 in 2024, then grew by 22.74% to $154780.0 in 2025.
  • Business Quant data shows Accumulated Expenses for ABVC at $154780.0 in Q3 2025, $160914.0 in Q2 2025, and $140252.0 in Q1 2025.